About This Information

This section provides supplementary clinical information for the Aimovig (erenumab) dosing calculator. The content below explains the calculator’s outputs, its intended use, and offers a broader clinical context for dosing decisions, administration, and safety considerations in the prophylactic treatment of migraine in adults.

Calculator Outputs Explained

The tool calculates and displays a complete dosing regimen based on the patient scenario selected:

• Recommended Dose: Specifies the monthly subcutaneous dose (70 mg or 140 mg).
• Administration Details: Provides instructions on how to administer the selected dose, noting that the 140 mg dose requires two separate 70 mg injections.
• Next Dose Date: For existing patients, it calculates the next scheduled monthly dose. If a dose is missed, it provides guidance and calculates a new schedule based on the current date.

How to Use the Calculator

Follow these steps to determine the correct dosing schedule:

1. Select Patient Scenario: Choose either “New Patient” for initiating therapy or “Existing Patient” for managing an ongoing treatment schedule.
2. Enter Patient Data:
   • For a new patient, select the intended starting dose (70 mg or 140 mg).
   • For an existing patient, select their current monthly dose and enter the date their last dose was administered.
3. Calculate: Click the “Calculate” button to generate the dosing regimen and next dose information.

Dosing Overview

Aimovig is administered subcutaneously once monthly. There are two available monthly doses:

• 70 mg Once Monthly: This is the recommended starting dose. It is administered as one 70 mg single-dose prefilled autoinjector or syringe.
• 140 mg Once Monthly: Some patients may benefit from a higher dose. This is administered as two separate, consecutive 70 mg injections.

No dose adjustment is necessary for patients with renal or hepatic impairment. A loading dose is not required.

Switching to Aimovig

There are no specific guidelines in the prescribing information for switching from other migraine prophylactics. The decision to switch should be based on clinical judgment, considering the previous medication’s half-life and mechanism of action. Typically, Aimovig can be started at the next scheduled dosing interval of the discontinued medication.

Missed Dose Protocol

If a scheduled dose of Aimovig is missed, the calculator’s logic aligns with the official prescribing information:

• Administer the missed dose as soon as possible.
• The subsequent monthly dosing schedule should be based on the date of the most recent administration.

The calculator automatically determines this new schedule for existing patients who have missed their dose.

Safety Alerts

Clinicians should be aware of the following key warnings and precautions associated with Aimovig:

• Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, angioedema, and rash, have been reported. If a serious reaction occurs, discontinue Aimovig immediately.
• Hypertension: Development of new-onset hypertension or worsening of pre-existing hypertension has been observed, some cases requiring emergency treatment. Blood pressure should be monitored.
• Constipation with Serious Complications: Severe constipation, potentially requiring hospitalization or surgery, has been reported. Monitor patients for severe constipation and manage promptly.

Frequently Asked Questions (FAQ)

References

• Aimovig (erenumab-aooe) US Prescribing Information. Amgen Inc. U.S. Food and Drug Administration.
• Aimovig® (erenumab-aooe) Healthcare Professional Site. Amgen and Novartis.
• Aimovig (erenumab) European public assessment report (EPAR). European Medicines Agency.
• Aimovig (erenumab) Product Monograph. Health Canada.